高危非肌层浸润性膀胱癌治疗的现状与展望

沈益君; 王彦浩

doi:10.16016/j.1000-5404.202106156

您当前的位置：

首页 >

文章列表页 >

高危非肌层浸润性膀胱癌治疗的现状与展望

专题报道：膀胱癌基础与临床研究 | 更新时间：2026-01-09

- 高危非肌层浸润性膀胱癌治疗的现状与展望
- Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect
- 第三军医大学学报 2021年43卷第23期页码：2507-2511
- 作者机构：
  
  200032 上海，复旦大学：附属肿瘤医院泌尿外科，上海医学院肿瘤学系
- 作者简介：
  
  [沈益君，博士，副主任医师，硕士研究生导师，美国MD Anderson癌症中心和德州大学医学院访问学者。担任中国临床肿瘤学会(CSCO)尿路上皮癌专家委员会委员，中国抗癌协会泌尿男生殖系肿瘤专业委员会膀胱癌学组委员，中国医师协会男科医师青年委员会委员，上海市医师协会泌尿外科医师分会委员，上海市泌尿外科临床质控中心督察组专家。《Journal of Clinical Oncology》中文版泌尿分册编委，《中华男科学杂志》通讯编委。作为课题负责人主持国家自然科学基金、上海市自然科学基金、上海申康重大临床研究项目、上海市卫计委等课题。在国内外专业刊物上以第一作者和通信作者发表论文30余篇，研究成果被纳入NCCN膀胱癌诊治指南。主编《浸润性膀胱癌》《泌尿系统肿瘤：基础与临床的转化》，参编《实用外科学》《实用肿瘤外科学》等专著。主要从事膀胱肿瘤诊断人工智能模型、尿液肿瘤标志物开发以及膀胱肿瘤新型治疗手段等方面的研究。E-mail：yijunshen@urocancer.orgSHEN Yijun, E-mail: yijunshen@urocancer.org
- 基金信息：
  
  促进市级医院临床技能与临床创新能力三年行动计划(SHDC2020CR4031)
- DOI：10.16016/j.1000-5404.202106156
  中图分类号： R730.5;R737.14
- 收稿：2021-06-20，
  
  修回：2021-10-14，
  
  纸质出版：2021-12-15
- 稿件说明：
移动端阅览
沈益君, 王彦浩. 高危非肌层浸润性膀胱癌治疗的现状与展望[J]. 第三军医大学学报, 2021,43(23):2507-2511.

Yijun SHEN, Yanhao WANG. Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect[J]. Journal of Third Military Medical University, 2021, 43(23): 2507-2511.
沈益君, 王彦浩. 高危非肌层浸润性膀胱癌治疗的现状与展望[J]. 第三军医大学学报, 2021,43(23):2507-2511. DOI： 10.16016/j.1000-5404.202106156.

Yijun SHEN, Yanhao WANG. Treatment of high-risk non-muscle invasive bladder cancer: current status and prospect[J]. Journal of Third Military Medical University, 2021, 43(23): 2507-2511. DOI： 10.16016/j.1000-5404.202106156.

摘要

大部分高危非肌层浸润性膀胱癌(non-muscle invasive bladder cancer，NMIBC)患者会接受经尿道膀胱肿瘤电切术，然后辅以卡介苗(Bacillus Calmette-Guerin，BCG)膀胱灌注治疗。但不可避免地，一部分患者不能接受卡介苗治疗或者卡介苗治疗失败。因此，根治性膀胱切除术成为唯一的选择。近年来免疫治疗、靶向治疗等方法在膀胱肿瘤治疗领域发展迅速。本文总结了目前高危NMIBC的定义、临床特点和治疗方式，回顾目前高危NMIBC患者的治疗进展，包括BCG治疗失败后新型治疗药物的探索等，提出当前治疗高危NMIBC面临的挑战，并对未来诊疗提出对策和展望。

Abstract

Most patients with high-risk non-muscle invasive bladder cancer (NMIBC) undergo transurethral resection of bladder tumor followed by intravesical adjuvant immunotherapy with Bacillus Calmette-Guerin (BCG). But inevitably

some patients can not receive BCG treatment or are doomed to fail BCG-therapy

consequently. So radical cystectomy becomes only treatment option available. In recent years

immunotherapy and targeted therapy have developed rapidly in the field of bladder tumor. In this article

we summarize the current definition

clinical features and treatment of high-risk NMIBC

review the current treatment progress

including the exploration of new therapeutic drugs after BCG treatment failure

and put forward the current challenges in the treatment and propose countermeasures and prospects for the future diagnosis and treatment of high-risk NMIBC.

关键词

Keywords

references

SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

BABJUK M, BURGER M, COMPÉRAT E M, et al . European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ )-2019 update[J ] . Eur Urol, 2019, 76(5): 6 39-657. DOI: 10.1016/j.eururo.2019.08.016..

TAN W S, RODNEY S, LAMB B, et al . Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia[J ] . Cancer Treat Rev, 2016, 47: 22-31. DOI: 10.1016/j.ctrv.2016.05.002.

CANTER D, EGLESTON B, WONG Y N, et al . Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis[J ] . Urol Oncol, 2013, 31(6): 866-870. DOI: 10.1016/j.urolonc.2011.07.009.

PANG K H, NOON A P. Re: radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study[J]. Eur Urol, 2018, 73(4): 636. DOI: 10.1016/j.eururo.2017.12.007.

KAMAT A M, SYLVESTER R J, BÖHLE A, et al . Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group[J ] . J Clin Oncol, 2016, 34(16): 1935-1944. DOI: 10.1200/jco.2015.64.4070.

BALAR A V,KAMAT A M, KULKARNI G S, et al . Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study[J ] . Lancet Oncol, 2021, 22(7): 919-930. DOI: 10.1016/s1470-2045(21)00147-9.

SINGH P, CATHERINE T, LERNER S P, et al . S1605: Phase Ⅱ trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer[J ] . J Clin Oncol, 2017, 35(15_suppl): TPS4591. DOI: 10.1200/jco.2017.35.15_suppl.tps4591.

LORIOT Y, NECCHI A, PARK S H, et al . Erdafitinib in locally advanced or metastatic urothelial carcinoma[J ] . N Engl J Med, 2019, 381(4): 338-348. DOI: 10.1056/nejmoa1817323.

NECCHI A, RAGGI D, GIANNATEMPO P, et al . Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study[J ] . Eur Urol Oncol, 2020. [Epub ahead of print ] . DOI: 10.1016/j.euo.2020.04.005.

WOODCOCK V K, PURSHOUSE K, BUTCHER C, et al . A phase Ⅰ study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC)[J ] . J Clin Onco l, 2019, 37(7_suppl): 406. DOI: 10.1200/jco.2019.37.7_suppl.406.

YIP W, ASHRAFI A, DANESHMAND S. High-grade T1 urothelial carcinoma: where do we stand? [J]. Curr Urol Rep, 2019, 20(12): 79. DOI: 10.1007/s11934-019-0945-x.

BOORJIAN S A, ALEMOZAFFAR M, KONETY B R, et al . Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial[J ] . Lancet Oncol, 2021, 22(1): 107-117. DOI: 10.1016/s1470-2045(20)30540-4.

BREE K K, BROOKS N A, KAMAT A M. Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer[J]. Hematol Oncol Clin North Am, 2021, 35(3): 513-529. DOI: 10.1016/j.hoc.2021.02.003.

LI R, ZHANG J S, GILBERT S M, et al . Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer[J ] . Nat Rev Urol, 2021, 18(9): 543-555. DOI: 10.1038/s41585-021-00483-z.

PACKIAM V T, LAMM D L, BAROCAS D A, et al . An open label, single-arm, phase Ⅱ multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in pa tients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results[J ] . Urol Oncol, 2018, 36(10): 440-447. DOI: 10.1016/j.urolonc.2017.07.005.

PATEL A, BISNO D I, PATEL H V, et al . Immune checkpoint inhibitors in the management of urothelial carcinoma[J ] . J Cancer Immunol(Wilmington), 2021, 3(2): 115-136. DOI: 10.33696/cancerimmunol.3.047.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肝细胞癌临床诊治新进展：综合治疗策略的演变

免疫治疗联合靶向治疗及化疗在微卫星稳定型转移性结直肠癌患者三线治疗中的疗效和安全性

中高危非肌层浸润性膀胱癌卡介苗灌注治疗后复发的临床预测模型构建与验证

阿尔茨海默病的A2G plus管理模式

PRKCH的表达对CD8+T细胞功能及黑色素瘤免疫治疗的影响